

IN THE CLAIMS

The claims are not amended at this time, but are presented below for the Examiner's convenience.

1. – 30. (Canceled)

31. (Previously Presented) A synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and which comprises the nucleotide sequence shown in SEQ ID NO: 10, wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide.

32. – 35. (Canceled)

36. (Previously Presented) The synthetic oligonucleotide of claim 31, wherein the oligonucleotide is up to 70 nucleotides in length.

37. (Previously Presented) The synthetic oligonucleotide of claim 31, wherein the oligonucleotide is up to 50 nucleotides in length.

38. (Canceled)

39. (Previously Presented) The synthetic oligonucleotide of claim 31, wherein the oligonucleotide is 30 nucleotides in length.

40. (Canceled)

41. (Canceled)

42. (Canceled)

43. (Previously Presented) A pharmaceutically acceptable salt of a synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide.
44. (Previously Presented) A pharmaceutically acceptable salt of the synthetic oligonucleotide of claim 31.
45. (Previously Presented) A pharmaceutically acceptable salt of the synthetic oligonucleotide of claim 39.
46. (Previously Presented) A pharmaceutical composition comprising a synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide, and a pharmaceutically acceptable carrier.
47. (Previously Presented) A pharmaceutical composition comprising the synthetic oligonucleotide of claim 31 and a pharmaceutically acceptable carrier.
48. (Previously Presented) A pharmaceutical composition comprising the synthetic oligonucleotide of claim 39 and a pharmaceutically acceptable carrier.
49. – 50. (Canceled)